The L.E.A.P.S. approach to vaccine development.

Daniel H. Zimmerman, Ken S. Rosenthal

Research output: Contribution to journalReview article

Abstract

The Ligand Epitope Antigen Presentation System (L.E.A.P.S.) approach to vaccine development utilizes immune peptides to promote the immunogenicity and influence the type of immune response generated towards epitopes in peptides which may be too small to elicit an immune response. The covalent attachment of these immune peptides to the antigenic peptide promotes the interaction of the epitope with T cells (T cell binding ligand (TCBL)) or antigen presenting cells (immune cell binding ligand (ICBL)) and ultimately promotes binding with the T cell receptor on CD4 or CD8 T cells. The, J, ICBL/TCBL peptide derived from the beta-2-microglobulin chain of MHC I molecules promotes Th1 type responses to the antigenic peptide while the, G, ICBL/TCBL peptide derived from the beta chain of MHC II molecules promotes Th2 types of responses. The efficacy of this approach has been demonstrated by characterization of the immune responses to L.E.A.P.S. vaccines and by elicitation of protection from infectious challenge with herpes simplex virus and other pathogens. The protection studies show that the L.E.A.P.S. approach allows customization of the immune response appropriate for inducing protection from disease. The theory, background, examples and studies of the mechanism of action of the L.E.A.P.S. vaccines will be discussed.

Original languageEnglish (US)
Pages (from-to)790-798
Number of pages9
JournalFrontiers in bioscience : a journal and virtual library
Volume10
DOIs
StatePublished - Jan 1 2005

Fingerprint

Antigen Presentation
Epitopes
Vaccines
Ligands
Antigens
T-cells
Peptides
T-Lymphocytes
beta 2-Microglobulin
Gastrin-Secreting Cells
Molecules
T-Lymphocyte Epitopes
Pathogens
Antigen-Presenting Cells
Simplexvirus
T-Cell Antigen Receptor
Viruses

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

The L.E.A.P.S. approach to vaccine development. / Zimmerman, Daniel H.; Rosenthal, Ken S.

In: Frontiers in bioscience : a journal and virtual library, Vol. 10, 01.01.2005, p. 790-798.

Research output: Contribution to journalReview article

Zimmerman, Daniel H. ; Rosenthal, Ken S. / The L.E.A.P.S. approach to vaccine development. In: Frontiers in bioscience : a journal and virtual library. 2005 ; Vol. 10. pp. 790-798.
@article{a2207626ce2b46fd92e3a8254fdc5411,
title = "The L.E.A.P.S. approach to vaccine development.",
abstract = "The Ligand Epitope Antigen Presentation System (L.E.A.P.S.) approach to vaccine development utilizes immune peptides to promote the immunogenicity and influence the type of immune response generated towards epitopes in peptides which may be too small to elicit an immune response. The covalent attachment of these immune peptides to the antigenic peptide promotes the interaction of the epitope with T cells (T cell binding ligand (TCBL)) or antigen presenting cells (immune cell binding ligand (ICBL)) and ultimately promotes binding with the T cell receptor on CD4 or CD8 T cells. The, J, ICBL/TCBL peptide derived from the beta-2-microglobulin chain of MHC I molecules promotes Th1 type responses to the antigenic peptide while the, G, ICBL/TCBL peptide derived from the beta chain of MHC II molecules promotes Th2 types of responses. The efficacy of this approach has been demonstrated by characterization of the immune responses to L.E.A.P.S. vaccines and by elicitation of protection from infectious challenge with herpes simplex virus and other pathogens. The protection studies show that the L.E.A.P.S. approach allows customization of the immune response appropriate for inducing protection from disease. The theory, background, examples and studies of the mechanism of action of the L.E.A.P.S. vaccines will be discussed.",
author = "Zimmerman, {Daniel H.} and Rosenthal, {Ken S.}",
year = "2005",
month = "1",
day = "1",
doi = "10.2741/1572",
language = "English (US)",
volume = "10",
pages = "790--798",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",

}

TY - JOUR

T1 - The L.E.A.P.S. approach to vaccine development.

AU - Zimmerman, Daniel H.

AU - Rosenthal, Ken S.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The Ligand Epitope Antigen Presentation System (L.E.A.P.S.) approach to vaccine development utilizes immune peptides to promote the immunogenicity and influence the type of immune response generated towards epitopes in peptides which may be too small to elicit an immune response. The covalent attachment of these immune peptides to the antigenic peptide promotes the interaction of the epitope with T cells (T cell binding ligand (TCBL)) or antigen presenting cells (immune cell binding ligand (ICBL)) and ultimately promotes binding with the T cell receptor on CD4 or CD8 T cells. The, J, ICBL/TCBL peptide derived from the beta-2-microglobulin chain of MHC I molecules promotes Th1 type responses to the antigenic peptide while the, G, ICBL/TCBL peptide derived from the beta chain of MHC II molecules promotes Th2 types of responses. The efficacy of this approach has been demonstrated by characterization of the immune responses to L.E.A.P.S. vaccines and by elicitation of protection from infectious challenge with herpes simplex virus and other pathogens. The protection studies show that the L.E.A.P.S. approach allows customization of the immune response appropriate for inducing protection from disease. The theory, background, examples and studies of the mechanism of action of the L.E.A.P.S. vaccines will be discussed.

AB - The Ligand Epitope Antigen Presentation System (L.E.A.P.S.) approach to vaccine development utilizes immune peptides to promote the immunogenicity and influence the type of immune response generated towards epitopes in peptides which may be too small to elicit an immune response. The covalent attachment of these immune peptides to the antigenic peptide promotes the interaction of the epitope with T cells (T cell binding ligand (TCBL)) or antigen presenting cells (immune cell binding ligand (ICBL)) and ultimately promotes binding with the T cell receptor on CD4 or CD8 T cells. The, J, ICBL/TCBL peptide derived from the beta-2-microglobulin chain of MHC I molecules promotes Th1 type responses to the antigenic peptide while the, G, ICBL/TCBL peptide derived from the beta chain of MHC II molecules promotes Th2 types of responses. The efficacy of this approach has been demonstrated by characterization of the immune responses to L.E.A.P.S. vaccines and by elicitation of protection from infectious challenge with herpes simplex virus and other pathogens. The protection studies show that the L.E.A.P.S. approach allows customization of the immune response appropriate for inducing protection from disease. The theory, background, examples and studies of the mechanism of action of the L.E.A.P.S. vaccines will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=33646936414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646936414&partnerID=8YFLogxK

U2 - 10.2741/1572

DO - 10.2741/1572

M3 - Review article

C2 - 15569618

AN - SCOPUS:33646936414

VL - 10

SP - 790

EP - 798

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

ER -